EuroapiEAPI
EAPI logo
Fair Value
€1
Share price16 Jun
€1.2525.2% overvalued intrinsic discount
Loading
1Y-61.83%
7D-5.86%

Rising Regulatory And Geopolitical Risks Will Undermine API Profits

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
12 Aug 25
Updated
16 Jun 26
Views
17
Not Invested

Fair Value vs Share Price

€1
vs €1.2525.2% overvalued intrinsic discount
PastFuture-287m994m2019202120232025202620272029Revenue €782.0mEarnings €1.9m
-2.8%
Revenue growth
0.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Euroapi

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Excellent balance sheet and good value.

Market cap€119.4m
PB0.2x
Estimated Growth-0.4%
Dividend YieldN/A
Full analysis

CEO & management

David Seignolle
CEO
1.5yrs
CEO Tenure

Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally.